General
Preferred name
ELOBIXIBAT
Synonyms
AZD 7806 ()
A 3309 ()
AZD-7806 ()
Elobixibat (hydrate) ()
A 3309 (hydrate) ()
AZD 7806 (hydrate) ()
A-3309 ()
AZD7806 ()
A3309 ()
P&D ID
PD058618
CAS
439087-18-0
1633824-78-8
Tags
available
drug
Approved by
PMDA
First approval
2018
Drug indication
Discovery agent
Constipation
Drug Status
approved
investigational
Max Phase
3.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Elobixibat is an orally available inhibitor of the ileal bile acid transporter (IBAT or ASBT), which is the protein product of the SLC10A2 gene. It is being evaluated for clinical utility in the management of chronic constipation . The chemical structure is claimed as Example 14 in Albireo Ab's patent US20130225511A1 (we have chosen this iteration of the patent as it has both chemical structure images and data included in online versions).
(GtoPdb)
DESCRIPTION
Elobixibat (A 3309; AZD 7806) is an orally effective Apical Sodium-Dependent Bile (IBAT) inhibitor, with an IC50 value of 0.53 nM (human IBAT ), 0.13 nM (mouse IBAT), 5.8 nM (canine IBAT). Elobixibat lowers LDL cholesterol, increases serum GLP-1, promotes colon motility, and has the potential to treat metabolic syndrome. Elobixibat can be used to study constipation, dyslipidemia, non-alcoholic hepatitis, and liver tumors[1][2][3].
PRICE
882
DESCRIPTION
Elobixibat hydrate is a potent ileal bile acid transporter (IBAT) inhibitor, with IC50 values of 0.53 ¡À 0.17 nM, 0.13 ¡À 0.03 nM, and 5.8 ¡À 1.6 nM for human IBAT, mouse IBAT, and canine IBAT. Elobixibat hydrate can be used for chronic idiopathic constipation (CIC) research[1].
DESCRIPTION
Elobixibat (A 3309) is an inhibitor of the ileal bile acid transporter (IC50: 0.13 nM, 0.53 nM, and 5.8 nM for mouse, human, and canine IBAT). Elobixibat can be used in studies about chronic idiopathic constipation.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
12
Cayman Chemical Bioactives
ChEMBL Drugs
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
DrugBank
DrugCentral
DrugCentral Approved Drugs
DrugMAP
Guide to Pharmacology
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
27
Molecular Weight
695.27
Hydrogen Bond Acceptors
8
Hydrogen Bond Donors
3
Rotatable Bonds
16
Ring Count
4
Aromatic Ring Count
3
cLogP
6.14
TPSA
142.11
Fraction CSP3
0.42
Chiral centers
1.0
Largest ring
7.0
QED
0.15
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
IBAT
Apical Sodium-Dependent Bile Acid Transporter
Interleukin Related
TNF Receptor
Pathway
Membrane Transporter/Ion Channel
Apoptosis
Immunology/Inflammation
Source data
